Tirzepatide vs Semaglutide: Liver Risk

A large real-world study comparing tirzepatide and injectable semaglutide in adults with overweight or obesity and type 2 diabetes found the two drugs carry the same risk of serious liver disease progression. The study, published in the journal Obesity on 19 August 2026, tracked new users of each drug and measured how often they went on to develop cirrhosis, a liver decompensation event, or liver cancer^[1]. Over a median follow-up of about 17 months, the two groups tracked almost exactly together: 4.05 events per 1,000 person-years on tirzepatide versus 4.04 on semaglutide^[1].

What counted as a 'major adverse liver outcome'

The researchers defined major adverse liver outcomes (MALO) as a composite of three hard endpoints: cirrhosis (permanent scarring that impairs how the liver functions), a decompensation event (a sign the scarred liver is struggling, such as fluid buildup in the abdomen, bleeding from enlarged veins, or confusion caused by a buildup of toxins the liver would normally clear), and hepatocellular carcinoma, the most common form of primary liver cancer^[1]. These are downstream, clinically serious consequences of long-term liver damage. They are a different, harder measure than the biopsy-based fibrosis and inflammation scores that most GLP-1 class liver trials report.

How the comparison was built

The study used a method called target trial emulation: the researchers designed the observational analysis to follow the same eligibility, treatment-start, and follow-up rules a real randomized trial would use, even though nobody was actually randomized. The underlying data came from TriNetX, a network that pools de-identified electronic health records from participating hospitals and health systems around the world^[1]. To keep the comparison fair, the authors used propensity score matching, a statistical technique that pairs a tirzepatide patient with a semaglutide patient who looks similar on measured factors, so a difference in outcomes is less likely to just reflect a difference in who started which drug in the first place.

What the numbers showed

The headline result was a hazard ratio of 1.04 (95% CI 0.88 to 1.23), meaning the study could not detect a meaningful difference in liver-outcome risk between the two drugs^[1]. The result held up in two further checks. Among patients who also had metabolic dysfunction-associated steatotic liver disease, or MASLD (fat buildup in the liver alongside a cardiometabolic risk factor such as obesity or diabetes)^[2], the incidence rates were 9.97 per 1,000 person-years on tirzepatide versus 10.03 on semaglutide (hazard ratio 1.03, 95% CI 0.75 to 1.42)^[1]. In an "as-treated" analysis, which only counts the time patients actually stayed on the drug rather than the time since they started it, the hazard ratio was 0.98 (95% CI 0.80 to 1.21)^[1]. Both drugs also clearly outperformed sitagliptin, an older diabetes medicine the authors used as an internal check on the analysis^[1].

Why the weight-loss gap did not translate into a liver-outcome gap

Tirzepatide produced a modestly larger drop in BMI than semaglutide in this study, about 1.1 kg/m2 more on average (P<0.001)^[1]. That tracks with what head-to-head weight-loss trials have already shown elsewhere: in SURMOUNT-5, a randomized trial in adults with obesity but without diabetes, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against 13.7% on semaglutide, a 6.5-percentage-point gap^[3]. It would be a reasonable guess that more weight loss means less liver damage, since excess weight is one of the main drivers of fatty liver disease. This study is a useful correction to that guess. Over roughly 17 months, a real BMI advantage for tirzepatide did not show up as a measurable advantage on hard liver outcomes. Liver scarring accumulates over years, and the gap between the two drugs may simply be too small, or the follow-up too short, for a weight difference of this size to move a slow-developing endpoint like cirrhosis.

What we don't yet know

This is one retrospective study, not a randomized trial, and it carries the limits that come with that design. Propensity score matching balances the factors the researchers could measure, not the ones hidden in the records, so residual confounding cannot be ruled out. A median follow-up of about 17 months is short for outcomes like cirrhosis and liver cancer, which typically take years to develop, so the comparison may simply be too early to catch a difference that only shows up later. The paper is also listed as ahead of print, and it appears to be the first study to compare these two drugs specifically on hard liver outcomes rather than fibrosis or steatohepatitis scores. Independent replication in another dataset would make the finding more solid.

What this means if you are on either drug

If you have type 2 diabetes and take tirzepatide or injectable semaglutide, this study is not a reason to switch drugs on liver grounds. Neither drug looked worse than the other for the hard liver outcomes the researchers tracked, and the weight-loss advantage tirzepatide has shown elsewhere did not translate into a detectable liver-outcome advantage here. Questions about liver disease risk, monitoring, or which drug fits your history belong with the clinician managing your diabetes and liver care, not with a drug-to-drug comparison read online.

This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide and semaglutide are prescription-only medicines in the countries PeptideMethods covers. Always consult a qualified healthcare professional before starting, stopping, or changing any medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.